On December 6, Sun Pharmaceutical Industries, Inc., revealed a licensing agreement with Aclaris Therapeutics, Inc., a biopharmaceutical firm focusing on innovative drugs for immuno-inflammatory diseases.
As per the pact, Aclaris grants Sun Pharma exclusive rights to specific patents for using deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, specifically for treating alopecia areata (AA) or androgenetic alopecia (AGA).
The deal includes a $15 million initial payment, along with subsequent regulatory and commercial milestones, as well as royalties, according to the company’s exchange filing.
